Clinical Trial Update: RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care [Phase 3]

View source ↗

Summary

An ongoing Phase 3 trial is evaluating whether dapagliflozin reduces recurrence of atrial fibrillation after cardioversion versus usual care; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Region Stockholm | Conditions: Atrial Fibrillation (AF) | Phase 3 | Status: RECRUITING